CanSino Biologics Inc.
6185Company Overview
The company (abbreviation: Cansino Biotech, stock code 6185.HK,688185.SH) was registered in Tianjin Binhai New Area in 2009 and is a national high-tech enterprise founded by a team of multinational pharmaceutical executives returning to China. With the mission of providing solutions to prevent infectious diseases and infectious diseases around the world, Cansino Biotech specializes in R&D, production and commercialization of high-quality human vaccines, and is a leading domestic high-tech biological products company. In March 2019, Cansino Biotech was listed on H shares on the main board of the Hong Kong Stock Exchange; on August 13, 2020, Cansino Biotech officially landed on the Science and Technology Innovation Board, becoming the first “A+H” vaccine stock since the launch of the Science and Technology Innovation Board. The company is an innovative vaccine enterprise dedicated to R&D, production and commercialization that meets Chinese and international standards. The company is gradually developing 17 innovative vaccine products for 12 indications to prevent Ebola virus disease, meningitis, COVID-19, tuberculosis, and shingles. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Group, etc.
Shariah Compliance Benchmarks:
- Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
- Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
This stock does not meet all Shariah compliance criteria according to AAOIFI standards.
| Name | CanSino Biologics Inc. |
| Ticker | 6185 |
| Main Business | Drug Manufacturers—Specialty & Generic |
| Type | Common Stock |
| Industry | Drug Manufacturers—Specialty & Generic |
| Country | HK |
| Market Cap | $0.75 B |
Shariah Analysis Breakdown
| Revenue Segment | Value ($M) | Non-Compliant ($M) | Reason |
|---|---|---|---|
| Sales of vaccine products | $1,031.0 | $0.0 | - |
| Other income | $156.9 | $0.0 | - |
| Finance income or gains | $184.7 | $184.7 | - |
| Total | $1,372.7 | $184.7 | 13.46% (failed) |
| Liability Item | Value ($M) | % of Market Cap |
|---|---|---|
| bank loans and overdrafts | $194,677,871.1 | 26.06% |
| long term bank loan | $149,859,944.0 | 20.06% |
| Total Interest-Bearing Debt | $344,537,815.1 | 46.12% |
| Market Capitalization | $747,108,653.8 | 100.00% |
| Compliance Status | Threshold: 33% | failed |